These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 2974704)
21. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Levin EC; Acharya NK; Han M; Zavareh SB; Sedeyn JC; Venkataraman V; Nagele RG Brain Res; 2010 Jul; 1345():221-32. PubMed ID: 20546711 [TBL] [Abstract][Full Text] [Related]
22. Neuronal and glial gene expression in neocortex of Down's syndrome and Alzheimer's disease. Goodison KL; Parhad IM; White CL; Sima AA; Clark AW J Neuropathol Exp Neurol; 1993 May; 52(3):192-8. PubMed ID: 8492138 [TBL] [Abstract][Full Text] [Related]
23. Ki-67 immunoreactivity in Alzheimer's disease and other neurodegenerative disorders. Smith TW; Lippa CF J Neuropathol Exp Neurol; 1995 May; 54(3):297-303. PubMed ID: 7745428 [TBL] [Abstract][Full Text] [Related]
24. Diagnostic utility of quantitating neurofilament-immunoreactive Alzheimer's disease lesions. de la Monte SM; Wands JR J Histochem Cytochem; 1994 Dec; 42(12):1625-34. PubMed ID: 7983363 [TBL] [Abstract][Full Text] [Related]
25. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. Snow AD; Mar H; Nochlin D; Sekiguchi RT; Kimata K; Koike Y; Wight TN Am J Pathol; 1990 Nov; 137(5):1253-70. PubMed ID: 2146882 [TBL] [Abstract][Full Text] [Related]
26. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. Russo C; Salis S; Dolcini V; Venezia V; Song XH; Teller JK; Schettini G Neurobiol Dis; 2001 Feb; 8(1):173-80. PubMed ID: 11162251 [TBL] [Abstract][Full Text] [Related]
28. Autoimmune thyroiditis associated with mild "subclinical" hypothyroidism in adults with Down syndrome: a comparison of patients with and without manifestations of Alzheimer disease. Percy ME; Dalton AJ; Markovic VD; Crapper McLachlan DR; Gera E; Hummel JT; Rusk AC; Somerville MJ; Andrews DF; Walfish PG Am J Med Genet; 1990 Jun; 36(2):148-54. PubMed ID: 2142381 [TBL] [Abstract][Full Text] [Related]
29. The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. Kim SH; Vlkolinsky R; Cairns N; Fountoulakis M; Lubec G Life Sci; 2001 May; 68(24):2741-50. PubMed ID: 11400916 [TBL] [Abstract][Full Text] [Related]
30. Intracellular calcium response is reduced in CD4+ lymphocytes in Alzheimer's disease and in older persons with Down's syndrome. Grossmann A; Kukull WA; Jinneman JC; Bird TD; Villacres EC; Larson EB; Rabinovitch PS Neurobiol Aging; 1993; 14(2):177-85. PubMed ID: 8098135 [TBL] [Abstract][Full Text] [Related]
31. Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice. Rueda N; Vidal V; García-Cerro S; Narcís JO; Llorens-Martín M; Corrales A; Lantigua S; Iglesias M; Merino J; Merino R; Martínez-Cué C Brain Behav Immun; 2018 Oct; 73():235-251. PubMed ID: 29758264 [TBL] [Abstract][Full Text] [Related]
33. The pathological association between Down syndrome and Alzheimer disease. Mann DM Mech Ageing Dev; 1988 May; 43(2):99-136. PubMed ID: 2969441 [TBL] [Abstract][Full Text] [Related]
34. The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease. Mann DM; Jones D; Prinja D; Purkiss MS Acta Neuropathol; 1990; 80(3):318-27. PubMed ID: 1698007 [TBL] [Abstract][Full Text] [Related]
35. Antibodies to neurofilaments. Talja I; Reimand T; Uibo O; Reimand K; Aun S; Talvik T; Janmey PA; Uibo R Ann N Y Acad Sci; 2009 Sep; 1173():130-6. PubMed ID: 19758141 [TBL] [Abstract][Full Text] [Related]
36. Developmental patterns of neuronal thread protein gene expression in Down syndrome. de la Monte SM; Xu YY; Hutchins GM; Wands JR J Neurol Sci; 1996 Feb; 135(2):118-25. PubMed ID: 8867067 [TBL] [Abstract][Full Text] [Related]
37. Decreased transcription factor junD in brains of patients with Down syndrome. Labudova O; Krapfenbauer K; Moenkemann H; Rink H; Kitzmüller E; Cairns N; Lubec G Neurosci Lett; 1998 Aug; 252(3):159-62. PubMed ID: 9739985 [TBL] [Abstract][Full Text] [Related]
38. Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype. Tramutola A; Pupo G; Di Domenico F; Barone E; Arena A; Lanzillotta C; Brokeaart D; Blarzino C; Head E; Butterfield DA; Perluigi M J Alzheimers Dis; 2016; 52(1):359-371. PubMed ID: 26967221 [TBL] [Abstract][Full Text] [Related]
39. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. Kálmán J; Juhász A; Laird G; Dickens P; Járdánházy T; Rimanóczy A; Boncz I; Parry-Jones WL; Janka Z Acta Neurol Scand; 1997 Oct; 96(4):236-40. PubMed ID: 9325475 [TBL] [Abstract][Full Text] [Related]